Follow the Money: Chimerix, Inc.
Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.
Chimerix, Inc. is a U.S. public pharmaceutical company that develops orally available antiviral medicines. As reported in the November 6, 2014 issue of the PharmSource Lead Sheet, Chimerix raised $121.7 million in the completion of a secondary public offering.
- Chimerix was incorporated in Delaware in April 2000.
- Corporate Headquarters: Durham, North Carolina – approximately 14,500 square feet of office space.
- Facility: Durham, North Carolina – 4,600 square feet of laboratory space.
- As of December 31, 2013, Chimerix had 52 employees, 39 of which were engaged in R&D activities.
- Chimerix plans to use the proceeds from the offering to fund its R&D activities, including current and planned clinical trials with brincidofovir, and for general corporate purposes, including working capital.
- The company relies on third parties to conduct, supervise, and monitor all clinical trials.
- Chimerix does not own or operate facilities for manufacturing, storage and distribution, or testing and relies on third-party manufacturers to produce preclinical and clinical drug supplies.
- The company intends to rely on third parties to produce commercial supplies of any approved product candidates.
- Chimerix has no sales, marketing, or distribution capabilities.
- In July 2012, Chimerix granted Merck worldwide rights to CMX157, a nucleoside phosphonate being developed for the treatment of HIV infection. Chimerix received $17.5 million upfront and is eligible to receive a total of $151.0 million in milestones.1
|Product Candidate||Indication||Dosage Form||Status||Next Anticipated Step|
|Lipid Technology and Chemical Library||Cytomegalovirus/BK virus||Oral||Discovery||TBA|
|Lipid Technology and Chemical Library||Influenza||Oral||Discovery||TBA|
|Lipid Technology and Chemical Library||Norovirus||Oral||Discovery||TBA|
|Lipid Technology and Chemical Library||Other viruses||Oral||Discovery||TBA|
|Brincidofovir (CMX001)||Cytomegalovirus and other viruses in solid organ transplants||Tablet||Preclinical||Phase III in planning|
|Brincidofovir (CMX001)||Ebola||Tablet||Preclinical||Exploratory protocol under development|
|Brincidofovir (CMX001)||Adenovirus||Tablet||Phase I||Pilot study ongoing; pivotal design under development|
|Brincidofovir (CMX001)||Cytomegalovirus and other viruses in hematopoietic cell transplants||Tablet||Phase III||Enrollment ongoing; data anticipated in H2 2015|
|Brincidofovir (CMX001)||Smallpox||Tablet||Phase III||TBA|
|(In $ thousands)||2013||2012|
|General & Administrative Expenditures||8,327||6,397|
|Total Operating Expenses||32,989||36,503|
1 Chimerix, Inc. Annual Report, SEC.gov
|Chimerix, Inc.||Key Officers|
|2505 Meridian Parkway, Suite 340||M. Michelle Berrey, MD, PhD, President & CEO, CMO|
|Durham, NC 27713, USA||Timothy W. Trost, SVP, CFO|
|Phone: 919-806-1074||Garrett Nichols, MD, CMO|
|Fax: 919-806-1146||Herve Mommeja-Marin, MD, VP, Clinical Research|
|Web: www.chimerix.com||Michael D. Rogers, PhD, Chief Development Officer|